Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Discoid Lupus Erythematosus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Discoid Lupus Erythematosus. Displaying page 1 of 1.
    EudraCT Number: 2006-007056-18 Sponsor Protocol Number: 3403 Start Date*: 2007-03-16
    Sponsor Name:The Newcastle upon tyne Hospitals NHS Trust
    Full Title: The Discoid Lupus Research Project
    Medical condition: Discoid lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003780-30 Sponsor Protocol Number: ASF-1096-203 Start Date*: 2006-09-05
    Sponsor Name:Astion Danmark A/S
    Full Title: Efficacy and safety of ASF-1096 cream 0.5 % in the treatment of patients with newly developed discoid lupus erythematosus (DLE) lesions. A multi-centre clinical phase 2, placebo controlled and doub...
    Medical condition: Lupus erthematosus discoides
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025138 Lupus erythematosus discoides LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001602-33 Sponsor Protocol Number: RR15/114 Start Date*: 2015-09-22
    Sponsor Name:The University of Leeds
    Full Title: A single arm, phase II open label trial to investigate the efficacy and safety of intra-dermal injection of etanercept for remission induction in discoid lupus erythematosus
    Medical condition: Discoid lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000071-21 Sponsor Protocol Number: IM011-132 Start Date*: 2021-03-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Participants with Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
    Medical condition: Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10056509 Cutaneous lupus erythematosus PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057903 Subacute cutaneous lupus erythematosus PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003833-25 Sponsor Protocol Number: EFACLE2008 Start Date*: 2009-02-05
    Sponsor Name:Universitätskrankenhaus Schleswig-Holstein
    Full Title: Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study
    Medical condition: Cutaneous lupus erythematosus (discoid LE or subacute cutaneous LE) or systemic lupus erythematosus with cutaneous DLE or SCLE lesions without major organ involvment.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013071 Discoid lupus erythematosis LLT
    9.1 10057903 Subacute cutaneous lupus erythematosus LLT
    9.1 10056509 Cutaneous lupus erythematosus LLT
    Population Age: Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-001062-17 Sponsor Protocol Number: ASF-1096-201/250912BS Start Date*: 2006-11-30
    Sponsor Name:Astion Danmark A/S
    Full Title: Efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with newly developed discoid lupus erythymatosus (DLE) lesions. A multi centre clinical phase 2, placebo controlled and doubl...
    Medical condition: Male or female patients with a clinical diagnosis of either Discoid Lupus Erythmatosus or Systemic Lupus Erythmatosus and at least one newly developed, sharply demarcated DLE lesion.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025138 Lupus erythematosus discoides LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000831-21 Sponsor Protocol Number: HZNP-DAX-202 Start Date*: 2023-02-06
    Sponsor Name:Horizon Therapeutics Ireland DAC
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF DAXDILIMAB SUBCUTANEOUS INJECTION IN REDUCING DISEASE ACTIVITY I...
    Medical condition: Discoid Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004858 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing) BG (Ongoing) PL (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-004648-27 Sponsor Protocol Number: MS200569_0003 Start Date*: 2022-03-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, Randomized, Double-Blind, Placebo Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous ...
    Medical condition: Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10056509 Cutaneous lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057903 Subacute cutaneous lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000239-21 Sponsor Protocol Number: MS200569_0048 Start Date*: 2022-10-18
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase 2, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants with Subacute Cutaneous Lupus Erythematosus, Discoid Lupu...
    Medical condition: Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10056509 Cutaneous lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057903 Subacute cutaneous lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023645-29 Sponsor Protocol Number: UKM 10_0020 Start Date*: 2011-03-15
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study
    Medical condition: Adult subjects of any ethnicity and either gender with Cutaneous Lupus Erythematosus lesions of Subacute Cutaneous Lupus Erythematosus (SCLE), Discoid Lupus Erythematosus (DLE), Lupus erythematosus...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10056509 Cutaneous lupus erythematosus LLT
    12.1 10056509 Cutaneous lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004359-32 Sponsor Protocol Number: 230LE201 Start Date*: 2017-02-01
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in...
    Medical condition: Systemic Lupus Erythematosus (SLE) with Active Skin Manifestations and Active Cutaneous Lupus Erythematosus (CLE) with or without Systemic Manifestations
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000328-16 Sponsor Protocol Number: 20170588 Start Date*: 2019-09-23
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
    Medical condition: Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Ongoing) PT (Prematurely Ended) GR (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024131-16 Sponsor Protocol Number: UKM10_0019 Start Date*: 2011-05-06
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study
    Medical condition: Αdult subjects of any ethnicity and either gender with Subacute Cutaneous Lupus Erythematosus (SCLE), Discoid Lupus Erythematosus (DLE), Lupus erythematosus tumidus (LET) or Systemic Lupus Erythema...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10040785 - Skin and subcutaneous tissue disorders 10056509 Cutaneous lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004703-14 Sponsor Protocol Number: ACT16404 Start Date*: 2021-05-12
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo controlled, proof of concept study assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chr...
    Medical condition: Cutaneous Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10056509 Cutaneous lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003615-22 Sponsor Protocol Number: EXP-1373 Start Date*: 2019-05-28
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy and safety of twice-daily application of delgocitinib cream 20 mg/g for 6 weeks in subjects with active discoid lupus erythematosus. A phase 2a exploratory, randomised, double-blind, vehi...
    Medical condition: Discoid lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000727-40 Sponsor Protocol Number: 230LE301 Start Date*: 2022-08-18
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A 2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants with Active Subacu...
    Medical condition: Subacute Cutaneous Lupus Erythematosus Chronic Cutaneous Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10056509 Cutaneous lupus erythematosus PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057903 Subacute cutaneous lupus erythematosus PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057929 Chronic cutaneous lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IT (Ongoing) BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004051-19 Sponsor Protocol Number: IM101-042 Start Date*: 2005-05-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc...
    Medical condition: SYSTEMIC LUPUS ERYTHEMATOSUS, NOS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) AT (Completed) IT (Prematurely Ended)
    Trial results: Removed from public view
    EudraCT Number: 2007-004635-29 Sponsor Protocol Number: ASF-1096-301 Start Date*: 2007-11-07
    Sponsor Name:Astion Pharma A/S
    Full Title: Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice dail...
    Medical condition: Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA